Kiniksa commence enrollment in Phase 2b trial of abiprubart

Kiniksa Pharmaceuticals announced that it has commenced enrollment of the Phase 2b clinical trial of abiprubart in Sjogren’s Disease. Abiprubart is an investigational humanized anti-CD40 monoclonal antibody designed to inhibit CD40-CD154 interaction. “Sjogren’s Disease is a debilitating, chronic autoimmune disorder currently with no FDA-approved therapies. Commencing the next phase of development of abiprubart in Sjogren’s Disease is an important step forward for patients,” said Sanj K. Patel, Chairman and Chief Executive Officer of Kiniksa. “This Phase 2b clinical trial builds on external mechanistic proof-of-concept as well as learnings from our own prior clinical data. Additionally, we believe abiprubart has the potential for differentiation in addressing unmet need through convenient subcutaneous administration. Importantly, our current operating plan includes clinical development of abiprubart in Sjogren’s Disease, and the company expects to remain cash flow positive on an annual basis.”